top of page

Occam Places Jeb Ledell as COO at Aveo Oncology

AVEO Oncology (Nasdaq: AVEO) is a commercial stage, oncology-focused biopharmaceutical company. Aveo was acquired by LG Chem for $600M in October of 2022.

In late 2021, Occam placed Jeb Ledell as COO of AVEO. Jeb joined AVEO from Enzyvant Therapeutics, a biotech company dedicated to developing novel, transformative regenerative therapies with rare diseases, where he served as COO. Prior to Enzyvant, Jeb served as COO at Compass Therapeutics and Horizon Discovery Group.

bottom of page